Somewhat Positive Press Coverage Somewhat Unlikely to Impact Atara Biotherapeutics (ATRA) Stock Price
News articles about Atara Biotherapeutics (NASDAQ:ATRA) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a news impact score of 0.21 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.8236359757287 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded down 4.42% during mid-day trading on Friday, reaching $16.20. The company’s stock had a trading volume of 198,994 shares. The stock’s market capitalization is $495.06 million. The company has a 50 day moving average price of $15.28 and a 200 day moving average price of $15.66. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). On average, equities research analysts anticipate that Atara Biotherapeutics will post ($3.89) earnings per share for the current fiscal year.
Several research firms recently commented on ATRA. Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, August 7th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Friday. BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Jefferies Group LLC restated a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday. Finally, ValuEngine cut Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $25.50.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Atara Biotherapeutics (ATRA) Stock Price” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-atara-biotherapeutics-atra-stock-price.html.
In other Atara Biotherapeutics news, EVP Christopher Haqq sold 6,000 shares of the firm’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $14.92, for a total transaction of $89,520.00. Following the completion of the transaction, the executive vice president now owns 362,080 shares in the company, valued at $5,402,233.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $15.54, for a total transaction of $68,376.00. Following the transaction, the chief executive officer now owns 737,767 shares of the company’s stock, valued at approximately $11,464,899.18. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,909 shares of company stock worth $810,518. 16.20% of the stock is owned by company insiders.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.